Piceatannol, a natural trans-stilbene compound, inhibits human glyoxalase I
Autor: | Atsushi Yoshimori, Hiroko Uchida-Maruki, Masahiko Sai, Haruka Akahane, Nami Shimada, Ryoko Takasawa, Takayuki Yamamoto, Sei-ichi Tanuma, Hikari Tanaka |
---|---|
Rok vydání: | 2016 |
Předmět: |
0301 basic medicine
Lung Neoplasms Clinical Biochemistry Pharmaceutical Science Biochemistry 03 medical and health sciences chemistry.chemical_compound Lactoylglutathione lyase 0302 clinical medicine Cell Line Tumor Drug Discovery Stilbenes Humans Glycolysis Enzyme Inhibitors Molecular Biology Cell Proliferation chemistry.chemical_classification Piceatannol biology Organic Chemistry Methylglyoxal Lactoylglutathione Lyase Active site 030104 developmental biology Enzyme chemistry 030220 oncology & carcinogenesis Cancer cell biology.protein Molecular Medicine Pharmacophore |
Zdroj: | Bioorganicmedicinal chemistry letters. 27(5) |
ISSN: | 1464-3405 |
Popis: | Human glyoxalase I (GLO I), a rate-limiting enzyme for detoxification of methylglyoxal (MG), a by-product of glycolysis, is known to be a potential therapeutic target for cancer. Here, we searched new scaffolds from natural compounds for designing novel GLO I inhibitors and found trans-stilbene scaffold. We examined the inhibitory abilities to human GLO I of commercially available trans-stilbene compounds. Among them, piceatannol was found to have the most potent inhibitory activity against human GLO I. Piceatannol could inhibit the proliferation of human lung cancer NCI-H522 cells, which are dependent on GLO I for survival, in a dose- and time-dependent manner. In addition, piceatannol more significantly inhibited the proliferation of NCI-H522 cells than that of NCI-H460 cells, which are less dependent on GLO I. Importantly, overexpression of GLO I in NCI-H522 cells resulted in less sensitive to the antiproliferative activity of piceatannol. Taken together, this is the first report demonstrating that piceatannol inhibits GLO I activity and the GLO I-dependent proliferation of cancer cells. Furthermore, we determined a pharmacophore for novel inhibitors of human GLO I by computational simulation analyses of the binding mode of piceatannol to the enzyme hot spot in the active site. We suggest that piceatannol is a possible lead compound for the development of novel GLO I inhibitory anticancer drugs. |
Databáze: | OpenAIRE |
Externí odkaz: |